Genscript Biotech (HK:1548) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Genscript Biotech Corporation has announced the resignation of Dr. Liu Zhenyu from his role as rotating chief executive officer, effective 31 December 2024, as he pursues personal career development. Dr. Li Zhu, the current Executive Director and chief strategy officer, will take over as chairman of Probio Technology Limited, a subsidiary of Genscript. The company expressed gratitude for Dr. Liu’s contributions, ensuring a smooth transition for its leadership and maintaining stability in its operations.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Time to Jump Ship,’ Says Investor About MicroStrategy Stock
- Nvidia and Microsoft: Why This Top Investment Firm Decided to Dump Shares
- Wells Fargo (NYSE:WFC) Departs Philadelphia Sports Arena
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
